GoodRx Holdings (GDRX) Receivables - Net (2019 - 2026)

GoodRx Holdings has disclosed Receivables - Net across 8 years of filings, most recently posting $182.1 million for Q2 2026.

• In Q2 2026, Receivables - Net fell 3.64% year-over-year to $182.1 million; the TTM figure through Jun 2026 stood at $182.1 million (down 3.64% YoY), while the FY2025 annual figure was $235.7 million, up 61.54% from the prior year.
• Receivables - Net came in at $182.1 million for Q2 2026 at GoodRx Holdings, down from $232.7 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $235.7 million in Q4 2025 to a low of $116.4 million in Q1 2023.
• Average Receivables - Net over 5 years is $154.2 million, with a median of $144.2 million recorded in 2023.
• Year-over-year, Receivables - Net surged 65.7% in 2022 and dropped 5.55% in 2023.
• Over 5 years, Receivables - Net stood at $117.1 million in 2022, then gained by 22.59% to $143.6 million in 2023, then climbed by 1.62% to $145.9 million in 2024, then jumped by 61.54% to $235.7 million in 2025, then slipped by 22.74% to $182.1 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $182.1 million in Q2 2026, $232.7 million in Q1 2026, and $235.7 million in Q4 2025.